Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
33
VRDN Quote, Financials, Valuation and Earnings
Last price:
$18.82
Seasonality move
:
6.62%
Day range:
$18.44 - $19.25
52-week range:
$9.90 - $34.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.15x
P/B ratio:
3.21x
Volume:
3M
Avg. volume:
2M
1-year change:
44.15%
Market cap:
$1.9B
Revenue:
$70.8M
EPS (TTM):
-$3.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$11.6M | -$0.96 | -75.11% | -2.35% | $37.24 |
|
BSX
Boston Scientific Corp.
|
$5.2B | $0.79 | 9.79% | 62% | $100.81 |
|
IMVT
Immunovant, Inc.
|
-- | -$0.62 | -- | -18.29% | $40.59 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.18 | 95.36% | -52.54% | $7.87 |
|
NTRB
Nutriband, Inc.
|
$765K | -$0.17 | 4.52% | -54.85% | $15.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.81 | -8.03% | -97.28% | $146.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
$18.84 | $37.24 | $1.9B | -- | $0.00 | 0% | 22.15x |
|
BSX
Boston Scientific Corp.
|
$62.82 | $100.81 | $94.5B | 32.82x | $0.00 | 0% | 4.74x |
|
IMVT
Immunovant, Inc.
|
$24.50 | $40.59 | $4.9B | -- | $0.00 | 0% | -- |
|
MRKR
Marker Therapeutics, Inc.
|
$1.32 | $7.87 | $21.7M | -- | $0.00 | 0% | 5.44x |
|
NTRB
Nutriband, Inc.
|
$3.63 | $15.00 | $46.5M | -- | $0.00 | 0% | 19.07x |
|
PSTV
Plus Therapeutics, Inc.
|
$3.56 | $146.88 | $22.3M | -- | $0.00 | 0% | 3.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
6.56% | 2.933 | 1.54% | 12.37x |
|
BSX
Boston Scientific Corp.
|
33.07% | 1.671 | 8.45% | 0.94x |
|
IMVT
Immunovant, Inc.
|
-- | 1.174 | -- | 15.03x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.671 | -- | 7.49x |
|
NTRB
Nutriband, Inc.
|
3.31% | 2.421 | 0.32% | 7.07x |
|
PSTV
Plus Therapeutics, Inc.
|
17.04% | 1.919 | 1.16% | 1.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRDN
Viridian Therapeutics, Inc.
|
-$188K | -$122.7M | -51.3% | -53.74% | -92991.67% | -$24.5M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
IMVT
Immunovant, Inc.
|
-$101K | -$114.4M | -73.11% | -73.12% | -- | -$92.3M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$1.9M | -77.25% | -77.25% | -170.75% | -$1.9M |
|
NTRB
Nutriband, Inc.
|
$63K | -$3.9M | -159.71% | -164.64% | -1121.15% | -$1.8M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$5.7M | -- | -- | -420.04% | -$6.3M |
Viridian Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VRDN or BSX?
Boston Scientific Corp. has a net margin of -77256.06% compared to Viridian Therapeutics, Inc.'s net margin of 12.68%. Viridian Therapeutics, Inc.'s return on equity of -53.74% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About VRDN or BSX?
Viridian Therapeutics, Inc. has a consensus price target of $37.24, signalling upside risk potential of 97.64%. On the other hand Boston Scientific Corp. has an analysts' consensus of $100.81 which suggests that it could grow by 60.48%. Given that Viridian Therapeutics, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Viridian Therapeutics, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 BSXBoston Scientific Corp.24 0 0 -
Is VRDN or BSX More Risky?
Viridian Therapeutics, Inc. has a beta of 1.166, which suggesting that the stock is 16.64% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.926%.
-
Which is a Better Dividend Stock VRDN or BSX?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or BSX?
Viridian Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Viridian Therapeutics, Inc.'s net income of -$102M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 22.15x versus 4.74x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M BSXBoston Scientific Corp.4.74x 32.82x $5.3B $670M
-
Which has Higher Returns VRDN or IMVT?
Immunovant, Inc. has a net margin of -77256.06% compared to Viridian Therapeutics, Inc.'s net margin of --. Viridian Therapeutics, Inc.'s return on equity of -53.74% beat Immunovant, Inc.'s return on equity of -73.12%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M IMVTImmunovant, Inc.-- -$0.61 $986.1M -
What do Analysts Say About VRDN or IMVT?
Viridian Therapeutics, Inc. has a consensus price target of $37.24, signalling upside risk potential of 97.64%. On the other hand Immunovant, Inc. has an analysts' consensus of $40.59 which suggests that it could grow by 63.99%. Given that Viridian Therapeutics, Inc. has higher upside potential than Immunovant, Inc., analysts believe Viridian Therapeutics, Inc. is more attractive than Immunovant, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 IMVTImmunovant, Inc.11 5 0 -
Is VRDN or IMVT More Risky?
Viridian Therapeutics, Inc. has a beta of 1.166, which suggesting that the stock is 16.64% more volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.666%.
-
Which is a Better Dividend Stock VRDN or IMVT?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or IMVT?
Viridian Therapeutics, Inc. quarterly revenues are $132K, which are larger than Immunovant, Inc. quarterly revenues of --. Viridian Therapeutics, Inc.'s net income of -$102M is higher than Immunovant, Inc.'s net income of -$110.6M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 22.15x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M IMVTImmunovant, Inc.-- -- -- -$110.6M
-
Which has Higher Returns VRDN or MRKR?
Marker Therapeutics, Inc. has a net margin of -77256.06% compared to Viridian Therapeutics, Inc.'s net margin of -154.36%. Viridian Therapeutics, Inc.'s return on equity of -53.74% beat Marker Therapeutics, Inc.'s return on equity of -77.25%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M -
What do Analysts Say About VRDN or MRKR?
Viridian Therapeutics, Inc. has a consensus price target of $37.24, signalling upside risk potential of 97.64%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 495.96%. Given that Marker Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is VRDN or MRKR More Risky?
Viridian Therapeutics, Inc. has a beta of 1.166, which suggesting that the stock is 16.64% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.471, suggesting its more volatile than the S&P 500 by 47.131%.
-
Which is a Better Dividend Stock VRDN or MRKR?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or MRKR?
Viridian Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Marker Therapeutics, Inc. quarterly revenues of $1.1M. Viridian Therapeutics, Inc.'s net income of -$102M is lower than Marker Therapeutics, Inc.'s net income of -$1.7M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 22.15x versus 5.44x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M
-
Which has Higher Returns VRDN or NTRB?
Nutriband, Inc. has a net margin of -77256.06% compared to Viridian Therapeutics, Inc.'s net margin of -1118.87%. Viridian Therapeutics, Inc.'s return on equity of -53.74% beat Nutriband, Inc.'s return on equity of -164.64%.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M NTRBNutriband, Inc.18.2% -$0.32 $7.8M -
What do Analysts Say About VRDN or NTRB?
Viridian Therapeutics, Inc. has a consensus price target of $37.24, signalling upside risk potential of 97.64%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 313.22%. Given that Nutriband, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Nutriband, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 NTRBNutriband, Inc.1 0 0 -
Is VRDN or NTRB More Risky?
Viridian Therapeutics, Inc. has a beta of 1.166, which suggesting that the stock is 16.64% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.948, suggesting its more volatile than the S&P 500 by 94.828%.
-
Which is a Better Dividend Stock VRDN or NTRB?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or NTRB?
Viridian Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Nutriband, Inc. quarterly revenues of $346.1K. Viridian Therapeutics, Inc.'s net income of -$102M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 22.15x versus 19.07x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M NTRBNutriband, Inc.19.07x -- $346.1K -$3.9M
-
Which has Higher Returns VRDN or PSTV?
Plus Therapeutics, Inc. has a net margin of -77256.06% compared to Viridian Therapeutics, Inc.'s net margin of -417.92%. Viridian Therapeutics, Inc.'s return on equity of -53.74% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRDNViridian Therapeutics, Inc.-142.42% -$1.08 $772.9M PSTVPlus Therapeutics, Inc.93.27% -$0.04 $4.8M -
What do Analysts Say About VRDN or PSTV?
Viridian Therapeutics, Inc. has a consensus price target of $37.24, signalling upside risk potential of 97.64%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VRDNViridian Therapeutics, Inc.14 1 0 PSTVPlus Therapeutics, Inc.3 1 0 -
Is VRDN or PSTV More Risky?
Viridian Therapeutics, Inc. has a beta of 1.166, which suggesting that the stock is 16.64% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.
-
Which is a Better Dividend Stock VRDN or PSTV?
Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRDN or PSTV?
Viridian Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Viridian Therapeutics, Inc.'s net income of -$102M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 22.15x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRDNViridian Therapeutics, Inc.22.15x -- $132K -$102M PSTVPlus Therapeutics, Inc.3.21x -- $1.4M -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
